Neuropsychiatric symptoms in mild cognitive impairment and early Alzheimer's disease: Clinical pattern and diagnostic implications

Donna de Levante Raphael; Donna de Levante Raphael

doi:10.3934/Neuroscience.2025032

AIMS Neuroscience

2025, Volume 12, Issue 4: 676-705. doi: 10.3934/Neuroscience.2025032

Previous Article Next Article

Review Topical Sections

Neuropsychiatric symptoms in mild cognitive impairment and early Alzheimer's disease: Clinical pattern and diagnostic implications

Donna de Levante Raphael ^,

Alzheimer's Foundation of America, Research Department, 322 8th Avenue, Floor 16, New York, NY 10001, USA

Received: 06 June 2025 Revised: 15 November 2025 Accepted: 04 December 2025 Published: 18 December 2025

Background
Alzheimer's disease (AD) and mild cognitive impairment (MCI) are widely recognized for their hallmark cognitive deficits, typically characterized by progressive cognitive deterioration. However, neuropsychiatric symptoms (NPS), including depression, apathy, anxiety, irritability, and sleep disturbances, are increasingly prevalent in the early stages of these conditions and significantly influence the disease trajectory and patient outcomes. Importantly, neuropsychiatric symptoms often precede overt memory loss by several years, with subtle mood and behavioral disturbances serving as early pre-diagnostic markers of an underlying Alzheimer's pathology. Their presence complicates the diagnosis, accelerates the disease progression, and intensifies the caregiver burden. However, distinguishing NPS arising from neurodegeneration and primary psychiatric disorders remains a profound diagnostic challenge, thus delaying timely intervention and obscuring early disease recognition.
Objective
This structured narrative review examines the diagnostic complexities, clinical impact, and current management of NPS in early-stage Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), alongside the biological underpinnings, clinical relevance, diagnostic challenges, and treatment perspectives. We argue that understanding and managing NPS is essential to improve the clinical outcomes, reduce the caregiver burden, and guide therapeutic innovation.
Methods
A structured narrative review of peer-reviewed studies published between 2012 and 2025 was conducted using PubMed, MEDLINE, Scopus, PsycINFO, Google Scholar, and CINAHL. The included studies investigated NPS prevalence, neurobiological correlations, and management strategies in individuals with AD or MCI.
Findings
NPS affects up to 80% of individuals with early AD or MCI, often preceding cognitive decline. The current management strategies heavily rely on non-pharmacological interventions such as caregiver support, behavioral activation, and structured routines, while pharmacological options remain limited by modest efficacy and safety concerns.
Discussion
Advancing knowledge of NPS and their association with cognitive decline is critical to establish more precise diagnostic criteria and to inform personalized therapeutic approaches. Future research should emphasize biomarker-driven diagnostics and the development of novel, targeted interventions that simultaneously address cognitive and neuropsychiatric domains to optimize outcomes for patients and caregivers. This study contributes to the field by reframing NPS as potential early biomarkers in the trajectory of MCI and dementia progression.
- Alzheimer's disease,
- depression,
- anxiety,
- neuropsychiatric symptoms of dementia,
- NPS,
- dementia,
- MCI,
- behavior,
- apathy
Citation: Donna de Levante Raphael. Neuropsychiatric symptoms in mild cognitive impairment and early Alzheimer's disease: Clinical pattern and diagnostic implications[J]. AIMS Neuroscience, 2025, 12(4): 676-705. doi: 10.3934/Neuroscience.2025032

Related Papers:

Abstract

Background

Alzheimer's disease (AD) and mild cognitive impairment (MCI) are widely recognized for their hallmark cognitive deficits, typically characterized by progressive cognitive deterioration. However, neuropsychiatric symptoms (NPS), including depression, apathy, anxiety, irritability, and sleep disturbances, are increasingly prevalent in the early stages of these conditions and significantly influence the disease trajectory and patient outcomes. Importantly, neuropsychiatric symptoms often precede overt memory loss by several years, with subtle mood and behavioral disturbances serving as early pre-diagnostic markers of an underlying Alzheimer's pathology. Their presence complicates the diagnosis, accelerates the disease progression, and intensifies the caregiver burden. However, distinguishing NPS arising from neurodegeneration and primary psychiatric disorders remains a profound diagnostic challenge, thus delaying timely intervention and obscuring early disease recognition.

Objective

This structured narrative review examines the diagnostic complexities, clinical impact, and current management of NPS in early-stage Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), alongside the biological underpinnings, clinical relevance, diagnostic challenges, and treatment perspectives. We argue that understanding and managing NPS is essential to improve the clinical outcomes, reduce the caregiver burden, and guide therapeutic innovation.

Methods

A structured narrative review of peer-reviewed studies published between 2012 and 2025 was conducted using PubMed, MEDLINE, Scopus, PsycINFO, Google Scholar, and CINAHL. The included studies investigated NPS prevalence, neurobiological correlations, and management strategies in individuals with AD or MCI.

Findings

NPS affects up to 80% of individuals with early AD or MCI, often preceding cognitive decline. The current management strategies heavily rely on non-pharmacological interventions such as caregiver support, behavioral activation, and structured routines, while pharmacological options remain limited by modest efficacy and safety concerns.

Discussion

Advancing knowledge of NPS and their association with cognitive decline is critical to establish more precise diagnostic criteria and to inform personalized therapeutic approaches. Future research should emphasize biomarker-driven diagnostics and the development of novel, targeted interventions that simultaneously address cognitive and neuropsychiatric domains to optimize outcomes for patients and caregivers. This study contributes to the field by reframing NPS as potential early biomarkers in the trajectory of MCI and dementia progression.

Conflict of interest

The authors declare no conflict of interest.

References

[1]	Budson AE, Solomon PR (2012) New criteria for Alzheimer disease and mild cognitive impairment: implications for the practicing clinician. Neurol 18: 356-363. https://doi.org/10.1097/NRL.0b013e31826a998d
[2]	Seritan AL (2023) Advances in the diagnosis and management of psychotic symptoms in neurodegenerative diseases: a narrative review. J Geriatr Psychiatry Neurol 36: 435-460. https://doi.org/10.1177/08919887231164357
[3]	Cummings JL, Mega M, Gray K, et al. (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314. https://doi.org/10.1212/WNL.44.12.2308
[4]	Zhang NK, Zhang SK, Zhang LI, et al. (2024) The neural basis of neuropsychiatric symptoms in Alzheimer's disease. Front Aging Neurosci 16: 1487875. https://doi.org/10.3389/fnagi.2024.1487875
[5]	Phan SV, Osae S, Morgan JC, et al. (2019) Neuropsychiatric Symptoms in Dementia: considerations for pharmacotherapy in the USA. Drugs R D 19: 93-115. https://doi.org/10.1007/s40268-019-0272-1
[6]	Liampas I, Dardiotis E, Siokas V, et al. (2025) Editorial: Neuropsychiatric symptoms and cognitive impairment. Front Neurol 16: 1680162. https://doi.org/10.3389/fneur.2025.1680162
[7]	Iravani B, Abdollahi E, Eslamdoust-Siahestalkhi F, et al. (2022) Neuropsychiatric Symptoms of Alzheimer's Disease and Caregiver Burden. Front Neurol 13: 877143. https://doi.org/10.3389/fneur.2022.877143
[8]	Ghahremani M, Nathan S, Smith EE, et al. (2023) Functional connectivity and mild behavioral impairment in dementia-free elderly. Alzheimers Dement Transl Res Clin Interv 9: e12371. https://doi.org/10.1002/trc2.12371
[9]	Sone D, Shinagawa S (2025) Seeking the neural basis of neuropsychiatric symptoms in dementia: neuroimaging findings and controversies. Front Aging Neurosci 17: 1633309. https://doi.org/10.3389/fnagi.2025.1633309
[10]	McGirr A, Nathan S, Ghahremani M, et al. (2022) Progression to dementia or reversion to normal cognition in mild cognitive impairment as a function of late-onset neuropsychiatric symptoms. Neurology 98: e2132-e2139. https://doi.org/10.1212/WNL.0000000000200256
[11]	Ramirez MK, Phipps CJ, Murman DL, et al. (2025) Structural neuroimaging correlates of neuropsychiatric symptoms in Alzheimer's disease: a systematic literature review. Dement Geriatr Cogn Disord 54: 255-269. https://doi.org/10.1159/000543160
[12]	Kamatham PT, Shukla R, Khatri DK, et al. (2024) Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: breaking the memory barrier. Ageing Res Rev 101: 102481. https://doi.org/10.1016/j.arr.2024.102481
[13]	Vattathil SM, Blostein F, Miller-Fleming TW, et al. (2025) GWAS links APOE to neuropsychiatric symptoms in mild cognitive impairment and dementia. Alzheimers Dement 21: e70329. https://doi.org/10.1002/alz.70329
[14]	Ismail Z, Smith EE, Geda Y, et al. (2016) Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria. Alzheimers Dement 12: 195-202. https://doi.org/10.1016/j.jalz.2015.09.009
[15]	Peters ME, Schwartz S, Han D, et al. (2015) Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry 172: 460-465. https://doi.org/10.1176/appi.ajp.2014.14040480
[16]	Ruthirakuhan M, Guan DX, Mortby M, et al. (2025) Updates and future perspectives on neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement 21: e70079. https://doi.org/10.1002/alz.70079
[17]	Aguzzoli CS, Ferreira PCL, Povala G, et al. (2023) Neuropsychiatric symptoms and microglial activation in patients with Alzheimer disease. JAMA Netw Open 6: e2345175. https://doi.org/10.1001/jamanetworkopen.2023.45175
[18]	Phillips ML, Swartz HA (2014) A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research. Am J Psychiatry 171: 829-843. https://doi.org/10.1176/appi.ajp.2014.13081008
[19]	Raulin AC, Doss SV, Trottier ZA, et al. (2022) ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. Mol Neurodegener 17: 72. https://doi.org/10.1186/s13024-022-00574-4
[20]	Tampi RR, Jeste DV (2022) Dementia is more than memory loss: neuropsychiatric symptoms of dementia and their nonpharmacological and pharmacological management. Am J Psychiatry 179: 528-543. https://doi.org/10.1176/appi.ajp.2022.0508
[21]	Lyketsos CG, Carrillo MC, Ryan JM, et al. (2011) Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement 7: 532-539. https://doi.org/10.1016/j.jalz.2011.05.2410
[22]	van Dalen JW, van Wanrooij LL, Moll van Charante EP, et al. (2018) Association of apathy with risk of incident dementia: a systematic review and meta-analysis. JAMA Psychiatry 75: 1012-1021. https://doi.org/10.1001/jamapsychiatry.2018.1877
[23]	Wong TS, Li G, Li S, et al. (2023) G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders. Signal Transduct Target Ther 8: 177. https://doi.org/10.1038/s41392-023-01427-2
[24]	Moretti R, Signori R (2016) Neural correlates for apathy: frontal–prefrontal and parietal cortical–subcortical circuits. Front Aging Neurosci 8: 289. https://doi.org/10.3389/fnagi.2016.00289
[25]	Sliz D, Hayley S (2012) Major depressive disorder and alterations in insular cortical activity: a review of current functional magnetic imaging research. Front Hum Neurosci 6: 323. https://doi.org/10.3389/fnhum.2012.00323
[26]	Trapp NT, Martyna MR, Siddiqi SH, et al. (2022) The neuropsychiatric approach to the assessment of patients in neurology. Semin Neurol 42: 88-106. https://doi.org/10.1055/s-0042-1745741
[27]	Rosenberg PB, Mielke MM, Appleby BS, et al. (2013) The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry 21: 685-695. https://doi.org/10.1016/j.jagp.2013.01.006
[28]	Totuk O, Sahin S (2025) Apathy in Neuropsychiatric Disorders: Clinical Characteristics, Neurobiological Mechanisms and Therapeutic Strategies. Behav Neurol 2025: 3788122. https://doi.org/10. 1155/bn/3788122
[29]	Majer R, Adeyi O, Bagoly Z, et al. (2020) Neuropsychiatric symptoms, quality of life and caregivers' burden in dementia. Open Med 15: 905-914. https://doi.org/10.1515/med-2020-0124
[30]	Cloak N, Schoo C, Al Khalili Y (2025) Behavioral and Psychological Symptoms in Dementia. StatPearls [Internet] . Treasure Island (FL): StatPearls Publishing.
[31]	Pallanti S, Marras A, Dickson SL, et al. (2021) Manifesto for an ECNP Neuromodulation Thematic Working Group (TWG): Non-invasive brain stimulation as a new super-subspecialty. Eur Neuropsychopharmacol 52: 72-83. https://doi.org/10.1016/j.euroneuro.2021.07.002
[32]	Wiels WA, Wittens MMJ, Zeeuws D, et al. (2021) Neuropsychiatric symptoms in mild cognitive impairment and dementia due to AD: relation with disease stage and cognitive deficits. Front Psychiatry 12: 707580. https://doi.org/10.3389/fpsyt.2021.707580
[33]	Pless A, Ware D, Saggu S, et al. (2023) Understanding neuropsychiatric symptoms in Alzheimer's disease: challenges and advances in diagnosis and treatment. Front Neurosci 17: 1263771. https://doi.org/10.3389/fnins.2023.1263771
[34]	Borda MG, Aarsland D, Tovar-Rios DA, et al. (2020) Neuropsychiatric symptoms and functional decline in Alzheimer's disease and Lewy body dementia. J Am Geriatr Soc 68: 2257-2263. https://doi.org/10.1111/jgs.16709
[35]	Krell-Roesch J, Syrjanen JA, Mielke MM, et al. (2020) Association between neuropsychiatric symptoms and functional change in older non-demented adults: Mayo Clinic Study of Aging. J Alzheimers Dis 78: 911-917. https://doi.org/10.3233/JAD-200764
[36]	U.S. CensusThe older population: 2020 (2023). [cited 2025 December 09]. Available from: https://www.census.gov/library/stories/2023/05/2020-census-united-states-older-population-grew.html
[37]	Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, et al. (2019) Institutionalization risk and costs associated with agitation in Alzheimer's disease. Alzheimers Dement Transl Res Clin Interv 5: 851-861. https://doi.org/10.1016/j.trci.2019.10.004
[38]	Wise EA, Yan H, Oh E, et al. (2024) Racial/ethnic differences in neuropsychiatric disturbances associated with incident dementia. Alzheimers Dement Diagn Assess Dis Monit 16: e12615. https://doi.org/10.1002/dad2.12615
[39]	Babulal GM, Zhu Y, Trani JF (2023) Racial and ethnic differences in neuropsychiatric symptoms and progression to incident cognitive impairment among community-dwelling participants. Alzheimers Dement 19: 3635-3643. https://doi.org/10.1002/alz.12988
[40]	Shaw AR, Perales-Puchalt J, Johnson E, et al. (2022) Representation of racial and ethnic minority populations in dementia prevention trials: a systematic review. J Prev Alzheimers Dis 9: 113-118. https://doi.org/10.14283/jpad.2021.49
[41]	Milani SA, Cantu PA, Berenson AB, et al. (2021) Gender differences in neuropsychiatric symptoms among community-dwelling Mexican Americans aged 80 and older. Am J Alzheimers Dis Other Demen 36: 15333175211042958. https://doi.org/10.1177/15333175211042958
[42]	Babulal GM, Quiroz YT, Albensi BC, et al. (2019) Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: update and areas of immediate need. Alzheimers Dement 15: 292-312. https://doi.org/10.1016/j.jalz.2018.09.009
[43]	Tao Y, Peters ME, Drye LT, et al. (2018) Sex differences in the neuropsychiatric symptoms of patients with Alzheimer's disease. Am J Alzheimers Dis Other Demen 33: 450-457. https://doi.org/10.1177/1533317518783278
[44]	Tsiknia AA, Edland SD, Sundermann EE, et al. (2022) Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression. Mol Psychiatry 27: 4314-4322. https://doi.org/10.1038/s41380-022-01675-8
[45]	Qian W, Schweizer TA, Fischer CE (2014) Impact of socioeconomic status on initial clinical presentation to a memory disorders clinic. Int Psychogeriatr 26: 597-603. https://doi.org/10.1017/S1041610213002299
[46]	Zajacova A, Lawrence EM (2018) The relationship between education and health: Reducing disparities through a contextual approach. Annu Rev Public Health 39: 273-289. https://doi.org/10.1146/annurev-publhealth-031816-044628
[47]	Salmon M, Sibeoni J, Harf A, et al. (2022) Systematic review on somatization in a transcultural context among teenagers and young adults: Focus on the nosography blur. Front Psychiatry 13: 897002. https://doi.org/10.3389/fpsyt.2022.897002
[48]	Erani F, Terao CM, Cooper S, et al. (2025) Neuropsychiatric symptom phenotypes for early detection of risk in older adults. Alzheimers Dement 21: e70869. https://doi.org/10.1002/alz.70869
[49]	Fisher DW, Dunn JT, Dong H (2024) Distinguishing features of depression in dementia from primary psychiatric disease. Discov Ment Health 4: 3. https://doi.org/10.1007/s44192-023-00057-y
[50]	Regier NG, Taylor JL, Szanton SL, et al. (2021) Pain in persons with dementia and the direct and indirect impacts on caregiver burden. Geriatr Nurs 42: 366-371. https://doi.org/10.1016/j.gerinurse.2021.01.007
[51]	Goodarzi Z, Ismail Z (2019) Neuropsychiatric aspects of Alzheimer's disease. Pract Neurol 5: 78-83.
[52]	Schaefer LA, Thakur T, Meager MR (2023) Neuropsychological assessment. StatPearls . StatPearls Publishing. [cited 2025 December 09]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513310/
[53]	Modrego PJ, de Cerio LD, Lobo A (2023) The interface between depression and Alzheimer's disease: A comprehensive approach. Ann Indian Acad Neurol 26: 315-325. https://doi.org/10.4103/aian.aian_326_23
[54]	Jack CR, Wiste HJ, Therneau TM, et al. (2019) Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA 321: 2316-2325. https://doi.org/10.1001/jama.2019.7437
[55]	Livingston G, Huntley J, Sommerlad A, et al. (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396: 413-446. https://doi.org/10.1016/S0140-6736(20)30367-6
[56]	Rosenberg PB, Nowrangi MA, Lyketsos CG (2015) Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits?. Mol Aspects Med 43–44: 25-37. https://doi.org/10.1016/j.mam.2015.05.005
[57]	Brier MR, Gordon B, Friedrichsen K, et al. (2016) Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Sci Transl Med 8: 338ra66. https://doi.org/10.1126/scitranslmed.aaf2362
[58]	Krell-Roesch J, Syrjanen JA, Rakusa M, et al. (2021) Association of cortical and subcortical β-amyloid with standardized measures of depressive and anxiety symptoms in adults without dementia. J Neuropsychiatry Clin Neurosci 33: 64-71. https://doi.org/10.1176/appi.neuropsych.20050103
[59]	Holmes C, Cunningham C, Zotova E, et al. (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology 73: 768-774. https://doi.org/10.1212/WNL.0b013e3181b6bb95
[60]	Ng A, Tam WW, Zhang MW, et al. (2018) IL-1β, IL-6, TNF-α and CRP in elderly patients with depression or Alzheimer's disease: systematic review and meta-analysis. Sci Rep 8: 12050. https://doi.org/10.1038/s41598-018-30487-6
[61]	Cummings J, Ritter A, Rothenberg K (2019) Advances in management of neuropsychiatric syndromes in neurodegenerative diseases. Curr Psychiatry Rep 21: 79. https://doi.org/10.1007/s11920-019-1058-4
[62]	Bora E, Yener GG (2017) Meta-analysis of social cognition in mild cognitive impairment. J Geriatr Psychiatry Neurol 30: 206-213. https://doi.org/10.1177/0891988717710337
[63]	Aupperle RL, McDermott TJ, White E, et al. (2023) The neuropsychology of anxiety: An approach–avoidance decision-making framework. APA Handbook of Neuropsychology: Neurobehavioral disorders and conditions: Accepted science and open questions . Washington, DC: American Psychological Association 767-787. https://doi.org/10.1037/0000307-036
[64]	Shaik MA, Anik FI, Hasan MM, et al. (2025) Advancing remote monitoring for patients with Alzheimer disease and related dementias: systematic review. JMIR Aging 8: e69175. https://doi.org/10.2196/69175
[65]	American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), Washington, DC (2013).
[66]	Better MA (2023) Alzheimer's disease facts and figures. Alzheimers Dement 19: 1598-1695. https://doi.org/10.1002/alz.13016
[67]	Dubois B, Hampel H, Feldman HH, et al. (2016) Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement 12: 292-323. https://doi.org/10.1016/j.jalz.2016.02.002
[68]	Serrano-Pozo A, Frosch MP, Masliah E, et al. (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1: a006189. https://doi.org/10.1101/cshperspect.a006189
[69]	Petersen RC, Caracciolo B, Brayne C, et al. (2014) Mild cognitive impairment: a concept in evolution. J Intern Med 275: 214-228. https://doi.org/10.1111/joim.12190
[70]	Roberts R, Knopman DS (2013) Classification and epidemiology of MCI. Clin Geriatr Med 29: 753-772. https://doi.org/10.1016/j.cger.2013.07.003
[71]	Kiloh LG (1961) Pseudo-dementia. Acta Psychiatr Scand 37: 336-351. https://doi.org/10.1111/j.1600-0447.1961.tb07367.x
[72]	Wells CE (1979) Pseudodementia. Am J Psychiatry 136: 895-900. https://doi.org/10.1176/ajp.136.7.895
[73]	Geda YE, Roberts RO, Knopman DS, et al. (2008) Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry 65: 1193-1198. https://doi.org/10.1001/archpsyc.65.10.1193
[74]	Alzheimer's Foundation of AmericaNeuropsychiatric Symptoms: A Caregiver's Guide (2025). [cited 2025 December 09]. Available from: https://alzfdn.org/neuropsychiatric-symptoms-a-caregivers-guide/
[75]	McCammon JM, Sive H (2015) Challenges in understanding psychiatric disorders and developing therapeutics: A role for zebrafish. Dis Model Mech 8: 647-656. https://doi.org/10.1242/dmm.019620
[76]	Carrarini C, Russo M, Dono F, et al. (2021) Agitation and dementia: prevention and treatment strategies in acute and chronic conditions. Front Neurol 12: 644317. https://doi.org/10.3389/fneur.2021.644317
[77]	Nelson JC, Devanand DP (2011) A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc 59: 577-585. https://doi.org/10.1111/j.1532-5415.2011.03355.x
[78]	Yan WJ, Ruan QN, Jiang K (2022) Challenges for artificial intelligence in recognizing mental disorders. Diagnostics 13: 2. https://doi.org/10.3390/diagnostics13010002
[79]	Schneider LS, Dagerman KS, Insel P (2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294: 1934-1943. https://doi.org/10.1001/jama.294.15.1934
[80]	Lanctôt KL, Agüera-Ortiz L, Brodaty H, et al. (2017) Apathy associated with neurocognitive disorders: recent progress and future directions. Alzheimers Dement 13: 84-100. https://doi.org/10.1016/j.jalz.2016.05.008
[81]	Kim TH, Head E, Stark CEL, et al. (2025) Late-life emergence of neuropsychiatric symptoms and risk of cognitive impairment in cognitively unimpaired individuals. Alzheimers Dement 21: e70619. https://doi.org/10.1002/alz.70619
[82]	Klimova B (2016) Mobile Health Devices for Aging Population Groups: A Review Study. Mobile Web and Intelligent Information Systems . Cham: Springer. MobiWIS 2016, Lecture Notes in Computer Science. https://doi.org/10.1007/978-3-319-44215-0_24

Reader Comments

Your name:*

Email:*
© 2025 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)